CXCL5-CXCR2 Signaling in Macrophage Cholesterol Efflux and Atherosclerosis: From Mechanism to Therapy
About This Grant
ABSTRACT Atherosclerosis, a primary driver of cardiovascular disease, results from the accumulation of lipids and immune dysregulation in arterial walls. Current therapies, such as statins, are limited in their ability to address immune-mediated mechanisms. Human genetic studies identify CXCL5 as a causal gene for coronary artery disease, with lower levels linked to severe disease. Our preliminary data show that CXCL5 enhances macrophage cholesterol efflux and prevents plaque progression in mouse models. This multi-PI proposal integrates systems biology, pharmacology, and atherosclerosis expertise to elucidate CXCL5- CXCR2 signaling mechanisms using multi-omics and CRISPR-Cas9 in human macrophages (Aim 1), maps CXCL5-dependent immune responses via single-cell RNA sequencing in mouse models and human data (Aim 2), and evaluates CXCL5’s therapeutic potential to prevent and reverse atherosclerosis in preclinical models (Aim 3), aiming to develop novel immune-based therapies for cardiovascular disease management.
Grant Summary
CXCL5-CXCR2 Signaling in Macrophage Cholesterol Efflux and Atherosclerosis: From Mechanism to Therapy is a NHLBI - National Heart Lung and Blood Institute grant providing up to $773K for university, nonprofit, healthcare org. Applications are due 2030-03-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $773K
2030-03-31
- 1Confirm your organization is eligible for CXCL5-CXCR2 Signaling in Macrophage Cholesterol Efflux and Atherosclerosis: From Mechanism to Therapy from NHLBI - National Heart Lung and Blood Institute, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NHLBI - National Heart Lung and Blood Institute before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NHLBI - National Heart Lung and Blood Institute's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
CXCL5-CXCR2 Signaling in Macrophage Cholesterol Efflux and Atherosclerosis: From Mechanism to Therapy: Frequently Asked Questions
Who is eligible for the CXCL5-CXCR2 Signaling in Macrophage Cholesterol Efflux and Atherosclerosis: From Mechanism to Therapy?
CXCL5-CXCR2 Signaling in Macrophage Cholesterol Efflux and Atherosclerosis: From Mechanism to Therapy is offered by NHLBI - National Heart Lung and Blood Institute and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the CXCL5-CXCR2 Signaling in Macrophage Cholesterol Efflux and Atherosclerosis: From Mechanism to Therapy provide?
CXCL5-CXCR2 Signaling in Macrophage Cholesterol Efflux and Atherosclerosis: From Mechanism to Therapy provides up to $773K per award from NHLBI - National Heart Lung and Blood Institute. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the CXCL5-CXCR2 Signaling in Macrophage Cholesterol Efflux and Atherosclerosis: From Mechanism to Therapy deadline?
Applications for CXCL5-CXCR2 Signaling in Macrophage Cholesterol Efflux and Atherosclerosis: From Mechanism to Therapy are due 2030-03-31 (open). Because deadlines can change, verify the date with the funder, NHLBI - National Heart Lung and Blood Institute, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the CXCL5-CXCR2 Signaling in Macrophage Cholesterol Efflux and Atherosclerosis: From Mechanism to Therapy?
To apply for CXCL5-CXCR2 Signaling in Macrophage Cholesterol Efflux and Atherosclerosis: From Mechanism to Therapy, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NHLBI - National Heart Lung and Blood Institute.